Publication: Clinical Trials Arena
The article examines how the U.S. pharmaceutical industry is adapting strategic priorities ahead of 2026 in response to evolving policy and market pressures. Key developments in 2025 — including tariffs, onshoring initiatives, and the implementation of a Most Favored Nation (MFN) drug-pricing framework — are reshaping how companies operate domestically and globally.
Executives and industry advisers highlighted that MFN pricing — aligning U.S. drug costs with prices in other developed nations — may prompt companies to adjust market strategies and investment decisions. These changes come at a time when the sector also faces drugs going off patent and pricing pressures that could influence R&D prioritization, clinical portfolios, and strategic investment choices moving into 2026.
Overall, firms are seeking resilience through policy engagement, diversification of supply chains, and recalibration of product strategies to navigate uncertainty and reinforce competitiveness in the critical U.S. market.
Published: December 22, 2025
Learn more about US Managed Markets Services
Navigating US managed markets requires understanding market dynamics, pricing strategies, and payer expectations. Certara’s expertise lies in crafting data-backed value propositions that resonate with key stakeholders. From early value assessments to ICER response frameworks, our comprehensive services provide a competitive edge.
